Navigation Links
Discovery could be key to bioterrorism defense

A collaborative research team from the Uniformed Services University of the Health Sciences (USU), the Australian Animal Health Laboratory (AAHL) and the National Cancer Institute (NCI) have made a major breakthrough in efforts to combat two deadly viruses that could be engineered for use as bioweapons. The team isolated the functional receptor for the Nipah and Hendra viruses--naturally occurring and highly pathogenic paramyxoviruses for which no treatments or vaccines are currently available.

Christopher C. Broder, Ph.D., associate professor in USU's Department of Microbiology, and his NIH-funded team of researchers and investigators demonstrated that a cell surface protein called Ephrin-B2 is a functional receptor for both the Hendra and Nipah viruses. Many animal species are vulnerable to these viruses, making the potential for amplification in intermediate hosts and transmission greater. Ephrin-B2 is highly conserved in animals, and this finding sheds light on how these viruses can infest such a wide range of hosts.

"In addition to our concern about Nipah and Hendra viruses as emerging global health and economic threats, we worry about their potential use as bioterror agents," stated Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, the arm of NIH that funded the research, in an NIH news release. "This work, funded through our biodefense research program, is a major step towards developing countermeasures to prevent and treat Nipah and Hendra viruses."

"Now that we've identified the cell receptor, we have a new target for activity, hopefully blocking the viruses from infecting cells," Dr. Broder explained. Team members Matthew Bonaparte, Ph.D., and Anthony Dimitrov, Ph.D., both at USU, identified the cell receptor by analyzing a human cell line that was resistant to virus infection against two susceptible cell lines. The results of the research were published in the July 26 edition of the Proce edings of the National Academy of Sciences.

"We identified genes that are coded for known and predicted cell surface proteins that were missing from the resistant cell line," Dr. Broder said. "The genes were put into cells that were then exposed to a live virus at AAHL."

Hendra virus was first isolated in 1994 when an outbreak of respiratory and neurologic disease emerged among horses and humans in Hendra, Australia, killing two people. Hendra recently reemerged in Queensland, Australia, and researchers there isolated the virus at the biosafety level 4 facility.

Nipah virus, which is similar to and in the same genus as Hendra, was initially isolated in 1999, when a large outbreak of encephalitis and respiratory illness occurred in Malaysia and Singapore, killing more than 100 people. Last year, two further Nipah virus outbreaks occurred in Bangladesh, killing roughly 75% of those infected. Scientists are disturbed by the fact that many of these recent cases involved human-to-human transmission of Nipah, which originates in bats.

Ephrin-B2 is found on cells in the central nervous system, as well as in cells lining blood vessels. It is essential for central nervous system development and blood vessel growth in the embryos of humans and other mammals.

Broder and his team are among only a handful of scientists focusing on the viruses, which have been under investigation by USU researchers since 2000. Broder is a principal investigator on one of six projects from the Mid-Atlantic Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases funded by NIH.

The research has led to two inventions on which USU and the Henry M. Jackson Foundation for the Advancement of Military Medicine have filed patent applications.

The first patent application, "Soluble forms of Hendra Virus and Nipah Virus G glycoprotein," covers the production and use of the soluble G glycoprotein. This protein has utility as a vacc ine, in the development of pharmaceutical compositions and in diagnostic assays. The second patent application, "Compositions and Methods for the Inhibition of Membrane Fusion by Paramyxoviruses," covers the use of a novel peptide sequence of the soluble F glycoprotein, to block fusion of the virus with the host cell. This peptide can be used as a prophylactic, and/or to treat infections, and antibodies developed using this peptide can be utilized in diagnostic assays.


'"/>

Source:Henry M. Jackson Foundation for the Advancement of Military Medicine


Related biology news :

1. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
2. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
3. UCSD Discovery Shows How Embryonic Stem Cells Perform Quality Control Inspections
4. Discovery Could Lead To Novel Approaches In HIV Treatment
5. Discovery Promises Simpler Therapy for Sickle Cell Disease
6. Discovery may lead to better Candidiasis drug
7. Protein Discovery Could Unlock The Secret To Better TB Treatment
8. Discovery clarifies role of peptide in biological clock
9. Eliminate Data Analysis Bottlenecks in Drug Discovery
10. Discovery of New Dopamine Action May Yield Alternative Psychiatric Drugs
11. Discovery of an American salamander where it shouldnt be: Korea
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2018)... ... 14, 2018 , ... Cognition Corporation ®, a software ... their NAVIGATE2018 conference. , Steve McRoberts, Group Head of Quality and ... Cognition’s annual user conference. An experienced quality and regulatory professional for over 20 ...
(Date:8/9/2018)... ... August 08, 2018 , ... Plum Alley Investments, an ... and healthcare companies, has invested in a sought-after $23 million Series A round ... Technology and Mammoth Biosciences , The biotech company is bringing to market the ...
(Date:8/7/2018)... ... August 06, 2018 , ... Passersby can’t help but notice ... University Edwardsville’s University Park. SIUE students are working the “Feedstock Diversity Showcase” that ... feedstocks represent conventional biofuels production, advanced biofuels production and cellulosic biofuels production. , ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... ... InTouchMD , the leading provider of data services, outreach and marketing ... Biotech Week Boston , September 4th – 7th at Hynes Convention Center in Boston, ... powerful all in one marketing solution. Pulse is a multi-use platform that helps biotech ...
(Date:8/7/2018)... ... August 06, 2018 , ... ... companies, announces the placement of Dr. Paul Harney as President, North America at ... growth strategy and enhancing client satisfaction. He was also named to Prescient’s Board ...
(Date:7/31/2018)... Ill. (PRWEB) , ... July 31, 2018 , ... ... cooking oil for 65 years, announces the launch of their new website. The ... the user experience throughout the site. Mahoney partnered with Proceed Innovative to build ...
(Date:7/25/2018)... ... July 25, 2018 , ... Vium, Inc. ... Digital Vivarium™ and Vium Cloud approach to accelerate preclinical drug discovery and development, ... the company announced the appointment of Jeff Caron to the newly formed role ...
Breaking Biology Technology: